ARTICLE | Targets & Mechanisms
AChE revisited
Why Neuro-Bio thinks it's time to revisit the role of AChE in AD
June 30, 2016 7:00 AM UTC
Neuro-Bio Ltd. has identified a peptide derived from AChE - the enzyme responsible for breaking down acetylcholine - and believes the fragment is the main pathological driver in Alzheimer's disease, acting upstream of β-amyloid and tau in the brain centers hit earliest in the disease.
The company, which was formed in 2013, is developing inhibitors of the peptide to create a disease-modifying therapy, and is seeking investors to help fund preclinical studies...